

**STAIR VI**  
STROKE TREATMENT  
ACADEMIC INDUSTRY ROUNDTABLE

***“Acute Stroke Treatment:  
A Time for Innovation”***

*Arlington, VA  
March 8<sup>th</sup> & 9<sup>th</sup> 2008*

**STAIR VI Program**

*Saturday, March 8<sup>th</sup> Morning*

**7:00—8:00 FULL BREAKFAST PROVIDED**  
*Salon A & B First Floor*

*All Sessions for the day are in Salons J & K*

**8:00—8:15 WELCOME — OVERVIEW OF CONFERENCE GOALS & IMPACT OF PRIOR STAIRS**

- Welcoming Remarks – Conference Chair – *Marc Fisher*
- Introduction – *Vladimir Hachinski*

**8:15—10:15 SESSION 1: UPDATING THE STAIR PRECLINICAL RECOMMENDATIONS**

*Session Co-chairs – D. Hess & T. Jacobs*

- An Assessment of the STAIR I Preclinical Recommendations and Suggested Modifications – *R. Traystman*
- Quality Control in Preclinical Studies – *M. MacLeod*
- Preclinical Testing of Devices – *M. Gounis*
- Industry Considerations for Preclinical Drug/Device Development – *G. Feuerstein*
- ROUNDTABLE PANEL DISCUSSION: “PRECLINICAL RECS. PAST AND PRESENT”  
*R. Traystman, M. McLeod, M. Gounis, G. Feuerstein, T. Kent, S. Finklestein, J. Aronowski*

**10:15—10:30 Refreshment Break** *Foyer Outside Salon J & K*

**10:30—11:00 ACUTE STROKE TREATMENT: A TIME FOR INNOVATIVE THINKING – *Joseph Broderick***  
Brief Discussion Moderated by *P. Gorelick*

**11:00—12:45 SESSION 2: IS THERE A FUTURE FOR NEUROPROTECTION?**

*Session Co-chairs – A. Bach & W. Koroshetz*

- Lessons from the NXY-059 Preclinical Development Program – *D. Howells*
- Can Neuroprotection Succeed As A Stand Alone Therapy? – *K. Lees*
- Pharmacological and Methodological Approaches to Future Neuroprotection Studies – *S. Savitz*
- Are Modest Benefits Likely To Be Observed With Neuroprotection Clinically Meaningful and Economically Viable? – *W. Wasiewski*
- ROUNDTABLE PANEL DISCUSSION: “NEUROPROTECTION’S FUTURE”  
*D. Howells, K. Lees, S. Savitz, W. Wasiewski, V. Skvortsova, A. Schneider, D. Hanley, J. Broderick*

**12:45—1:45 LUNCHEON PROVIDED – Sponsored by Legend Merchant Group**  
*Salon 1 & 2*

*Guest Speaker  
Tom Gallagher, President*

# STAIR VI

STROKE TREATMENT  
ACADEMIC INDUSTRY ROUNDTABLE

## “Acute Stroke Treatment: A Time for Innovation”

*Saturday, March 8<sup>th</sup> Afternoon*

Salon J & K

1:45—3:45    **SESSION 3: STRATEGIES FOR EXTENDING THE THERAPEUTIC TIME WINDOW FOR DRUGS AND DEVICES**

*Session Co-chairs – H. Altman & R Sacco*

- **Is Penumbral Imaging Necessary for Extending the Therapeutic Time Window? – Pro Vs. Con**  
*Pro: C. Kidwell    Con: P. Lyden*
- **Penumbral Imaging: MRI, CT or Both? – M. Wintermark**
- **Current Phase II/III Trials With or Without Penumbral Imaging– W. Schabitz**
- **Regulatory Perspectives on Penumbral Imaging-Based Stroke Trials – B. Dunn, FDA**
- **ROUNDTABLE PANEL DISCUSSION: “EXTENDING THE THERAPEUTIC WINDOW”**  
*C. Kidwell, P. Lyden, M. Wintermark, W. Schabitz, B. Dunn, W. Söehngen, S. Warach, D. Levy*

3:45—4:00    **Refreshment Break**    *Foyer Outside Salon J & K*

4:00—6:00    **SESSION 4: NOVEL DEVICE & DRUG THERAPIES TO IMPROVE STROKE OUTCOME**

*Session Co-chairs – L. Goldstein & A. Weiss*

- **Laser Light Therapy – J. Zivin**
- **Electrical Cortical Stimulation – B. Kissela**
- **Aortic Balloon Occlusion – D. Liebeskind**
- **Drug Therapy to Enhance Recovery – S. Cramer**
- **Sphenopalatine Ganglion Stimulation – N. Bornstein**
- **ROUNDTABLE PANEL DISCUSSION: “DEVICES TO TREAT ACUTE STROKE”**  
*J. Zivin, N. Bornstein, D. Liebeskind, S. Cramer, B. Kissela, J. Marler, W. Smith, P. Rumm*

6:30—7:30    **SPONSORED RECEPTION – Sponsored By Bio-Imaging Technologies, Inc.**

Salon F, G, H

7:30—9:30    **DINNER -- Master of Ceremonies: Stroke Treatment Idol – Rick Atkinson**

Salon C, D, E

**S T A I R VI**  
STROKE TREATMENT  
ACADEMIC INDUSTRY ROUNDTABLE

***“Acute Stroke Treatment:  
A Time for Innovation”***

**Day 2**

***Sunday, March 9<sup>th</sup> Morning***

***7:30—8:30 BREAKFAST PROVIDED  
Salon C,D,E***

***All Participants: Please Convene in the Ballroom Prior to Going to Your Workshop***

**8:30 – 10:30 WORKSHOPS TO DEVELOP CONSENSUS RECOMMENDATIONS**  
Participants are divided into three groups – each to develop recommendations

**Workshop 1: Recommendations for Preclinical Research:**  
**Red Group** **Updating and Expanding the STAIR Preclinical Recommendations**  
**Salon F** ***E. Lo, D. Howells, P. Hurn***

**Workshop 2: Recommendations for Therapeutic Time Window Extension:**  
**Blue Group** **Acute Stroke Therapy Trials Beyond 3 Hours – What Should We Test & How Should We Test IT?**  
**Salon G** ***G. Albers, G. Howard, J. Saver***

**Workshop 3: Recommendations for Regulatory & Organizational Aspects:**  
**Green Group** **Acute Stroke Therapy Trials Beyond 3 Hours: Regulatory and Organizational Aspects**  
**Salon J & K** ***T. Furlan, K. Johnston, M. Walton***

**10:30 – 11:00 Refreshment Break** ***Foyer Outside Salon J & K***

**11:00—12:15 WORKSHOP CHAIRS PRESENT RECOMMENDATIONS** from their group with  
**Salon J & K** general discussion. Drafting of consensus statement is initiated.  
***Chaired by M. Fisher***

**12:15—12:30 CLOSING COMMENTS AND ADJOURNMENT**

————— ***Thank You for Your Participation*** —————